| 摘要 |
<p>Use of the determination of protease activity of proteasome for standardization and/or examination of one or more preparation affecting immune system by examining its effect on the protease activity of proteasomes in vitro, and as a biomarker for the treatability with one or more preparation affecting immune system, is claimed, where the effect of addition of the preparation is measured and compared with previously determined standard values, and a tissue or liquid sample is tested in vitro to evaluate the modulation of the protease activity of proteasomes by the addition of the preparation. Independent claims are included for: (1) standardization and/or examination of one or more preparation affecting immune system by examining its effect on the protease activity of proteasomes in vitro, where the presence or absence of a modulation of protease activity of proteasomes is measured by the addition of the preparation and compared with standard values; (2) a kit containing one or more fluorogenic substrates for determining at least one of the protease activity comprising trypsin-like, after branched chain-splitting and between neutral amino acid cleaving activity or chymotrypsin-like and caspase-like activity of proteasomes, preferably at 20S or 26S proteasomes, to determine the change of protease activity of proteasomes as a biomarker for the treatability of a subject with the preparation affecting the immune system, preferably a thymus or leukocyte extract; and (3) use of a fluorogenic substrate, preferably for the production of a diagnostic or a kit for determining at least one of protease activity comprising trypsin-like, after branched chain-splitting and between neutral amino acid cleaving activity or chymotrypsin-like and caspase-like activity of proteasomes as a biomarker for the treatability of a subject with the preparation affecting the immune system, preferably a thymus or leukocyte extract.</p> |
